Oxcarbazepine
As of the edition of 20 October 2026, Oxcarbazepine is a small molecule: marketed, first approved in 1994 (BR); acts on SCN10A, SCN11A and SCN1A and 7 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Trileptal
- First approved
- 24 August 1994 (BR)
- Approvals on record
- 14 in 6 regions
- Holder of the most recent approval
- Nobelpharma; 5 holders in all
- Registered trials
- 44, 4 stopped early
- Disease areas
- Nervous system; Mental health; Immune system; Injuries; Mouth and teeth; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
10 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product10 company-target rows are on route B because of Oxcarbazepine.
See the 10 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| SCN1A | Sodium channel protein type 1 subunit alpha | P35498 |
| SCN4A | Sodium channel protein type 4 subunit alpha | P35499 |
| SCN7A | Sodium channel protein type 7 subunit alpha | Q01118 |
| SCN5A | Sodium channel protein type 5 subunit alpha | Q14524 |
| SCN9A | Sodium channel protein type 9 subunit alpha | Q15858 |
| SCN2A | Sodium channel protein type 2 subunit alpha | Q99250 |
| SCN3A | Sodium channel protein type 3 subunit alpha | Q9NY46 |
| SCN11A | Sodium channel protein type 11 subunit alpha | Q9UI33 |
| SCN8A | Sodium channel protein type 8 subunit alpha | Q9UQD0 |
| SCN10A | Sodium channel protein type 10 subunit alpha | Q9Y5Y9 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 7 | 1 | 1 |
| Phase 1 | 7 | 6 | 0 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 9 | 6 | 1 | 2 |
| Phase 4 | 17 | 12 | 1 | 0 |
| All trials | 44 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Applicant and Lead sponsor of trials | 2000 to now |
| Supernus Pharmaceuticals | Later holder and Lead sponsor of trials | 2009 to now |
| Nobelpharma | Applicant and Lead sponsor of trials | 2010 to now |